Synnovation Therapeutics

Synnovation Therapeutics is a biotechnology startup founded in 2021 and headquartered in the United States. The company's slogan "A precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers" encapsulates its core mission. Synnovation Therapeutics specializes in developing small molecule therapies to target validated disease mechanisms in cancer, with the aim of achieving best-in-class pharmacology. The company boasts a deep understanding of cancer biology and a team of world-class medicinal chemists, enabling the development of a diverse pipeline of targeted therapies. The recent Series A investment of $102.00M on 14 December 2023 attracted a strong consortium of investors including Lilly Asia Ventures, Third Rock Ventures, Sirona Capital, Cormorant Asset Management, and Nextech Invest. This substantial investment reflects the confidence of industry players in Synnovation Therapeutics' approach to precision medicine and its potential to revolutionize cancer care. Overall, Synnovation Therapeutics is dedicated to advancing patient-focused precision medicine through the efficient development of novel small molecule targeted therapies, and the recent Series A investment underscores the industry's recognition of the company's potential to make a significant impact in the biotechnology and healthcare sectors.